Skipping chemo after surgery for ER+ HER2- breast cancer
Treatments studied
Part of Cancer clinical trials.
This study tests whether some people with a certain type of breast cancer (ER-positive, HER2-negative) can safely skip chemotherapy. After surgery, they receive a targeted pill (ribociclib) plus hormone therapy instead. The goal is to see if this approach works just as well with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have had surgery (mastectomy or lumpectomy) for your breast cancer
- Your tumor is ER-positive and HER2-negative (ask your doctor to confirm)
- You have not had chemotherapy before this surgery
- You are in generally good health (able to do daily activities)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a faster, higher-frequency chemotherapy schedule given before surgery for HER2-negative breast cancer. It aims to see if this approach works better and is safe for the patient’s cancer stage.
This trial tests if women with a common type of breast cancer (HR+/HER2-) can safely skip chemotherapy after surgery by taking targeted medication (ribociclib) plus hormone therapy. A special blood test called ctDNA helps doctors decide if chemo isn't needed.
This trial tests whether skipping chemotherapy is safe for women with a specific type of early-stage breast cancer (ER-positive, HER2-negative) that has spread to 1–3 lymph nodes. Instead of chemo, you would receive a targeted pill called abemaciclib after standard hormone therapy.
This trial tests whether women with certain aggressive breast cancers (HER2-positive without hormone receptors, or triple-negative) can safely skip breast surgery if chemotherapy makes their tumor completely disappear. The goal is to avoid surgery and its side effects when it may no longer be needed.
This trial tests whether some people with hormone receptor-positive, HER2-negative early breast cancer can safely receive less chemotherapy when also taking the targeted drug ribociclib after surgery. You may qualify if you have a specific stage of breast cancer and are planning to take hormone therapy for at least 5 years.
This trial tests whether it is safe to skip chemotherapy after surgery for certain patients with early-stage, hormone-receptor positive, HER2-negative breast cancer that has not spread to lymph nodes. Instead, they would receive hormone therapy plus a targeted CDK4/6 inhibitor (a pill that blocks cancer cell growth).
Hear when a new HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.